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Summary Topiramate was assessed in an open-label trial as broad-spectrum anti-
epileptic monotherapy, independently from the epilepsy type or syndrome. Adults
and children aged 2 years and older, who were diagnosed with epilepsy within the last
5 years, treatment-naive or failing prior treatment with one antiepileptic drug (AED),
received individually adjusted doses of topiramate, after escalation to 100 mg/day
over 4 weeks (maximum 400 mg/day) or 3 mg/kg/day over 6 weeks (maximum 9 mg/
kg/day), respectively. Patients were followed for 7 months and optionally up to a
maximum of 13 months. Data were analysed for all patients (n = 692), as well as for
focal (n = 421) and generalized epilepsies (n = 148).
The median topiramate dose used was 125 mg/day in adults and 3.3 mg/kg/day in
children (12 years). Overall, 80% of patients completed the 7-month study. During
this period, 44.3% were seizure-free, while 76.3% achieved 50% reduction in mean
monthly seizure frequency. Patients with focal and generalized epilepsies alike
responded to treatment (73.9 and 83.8% with at least 50% seizure reduction):
39.4% of patients with focal epilepsy and 61.5% of those with generalized epilepsy
were seizure-free. The mean monthly seizure frequency was significantly reduced
versus baseline at all visits ( p < 0.001). Similar response rates were obtained from the
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237 patients completing the 1-year observation period. During the mandatory 7-
month period of study, 8.8% of patients reported insufficient tolerability as a reason
for dropout. The most frequent adverse event was paraesthesia.
Our results support findings that emerge from controlled studies that topiramate is
effective and well tolerated when used as initial or second monotherapy. They also
suggest that in a naturalistic setting, overall good retention on treatment and seizure
freedom are observed at low doses in a broad spectrum of epilepsies.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Controlled double-blind trials for establishing effi-
cacy in epilepsy commonly use fixed target doses in
patients with a particular type of seizures. In clinical
practice, however, patients eligible for monother-
apy often do not yet have a clearly determined type
of seizures or epilepsy syndrome at the time of drug
initiation: accurate diagnosis develops over time.1
Treatment is not only guided by the efficacy for the
suspected epilepsy type, but also by the easiness of
titration, the potential for pharmacokinetic inter-
actions and the patient’s individual response, with
respect to both seizure control and tolerability.2—4
Topiramate is a newer AED with a broad pharma-
cological profile, thereby providing the rationale for
use as broad-spectrum anti-epileptic monotherapy.
It is a sulfamate-substituted monosaccharide, with
multiple mechanisms of action that include block-
ade of voltage-sensitive sodium channels,5 poten-
tiation of GABAA-evoked chloride flux,
6,7 blockade
of kainate/AMPA type of glutamate receptors,8 and
reduction of type L-calcium channels activity.9 It
also inhibits carbonic anhydrase.10
As monotherapy, topiramate has been studied in
patients with recent-onset epilepsy (within 3
months of study entry, maximum 2 years in one
study), different age limits (either 3, 6 or 16 years),
and various seizure types.11—14 These trials support
a clinical efficacy of topiramate monotherapy in a
broad range of dose strengths, usually established
after titration to a fixed target dose (50, 100, 200,
400, 500 or 1000 mg/day). High doses of topiramate
(1000 mg/day and 200—500 mg/day) were signifi-
cantly more effective than low doses (100 mg/day
and 25—50 mg/day, respectively) in reducing sei-
zure frequency and time to exit due to seizures,
but produced higher rates of side effects.11,12,14
In most European countries, topiramate is indi-
cated for adults and children as young as 2 years of
age. It is authorised for adjuvant treatment of
partial onset seizures with or without secondary
generalisation, primary generalised tonic-clonic sei-
zures and Lennox—Gastaut syndrome. More
recently, it has also been approved as monotherapy
for the same clinical conditions in a number ofcountries. The American Academy of Neurology
and the American Epilepsy Society considered topir-
amate as one of the monotherapy options for newly
diagnosed adolescents and adults with partial or
mixed seizure disorders.3,4 Topiramate is the only
AED that was retained for recommendation in the
refractory types of partial and generalized epilepsy,
and in Lennox Gastaut syndrome.4
The objective of this study was to generate
information on dose and outcome of topiramate
monotherapy in a naturalistic setting: i.e. when
topiramate is used as broad-spectrum AED at an
individually adjusted dose, independently of initial
seizure frequency and specific epilepsy type or
syndrome. Although the limitations of such global
treatment approach are recognized due to different
prognoses by age and type of epilepsy, it reflects the
reality of clinical practice in many countries where
the degree of diagnostic ascertainment of specific
epilepsy syndromes when treatment is initiated is
low. An additional objective was thus to expand the
current knowledge of response to topiramate in the
most frequent epilepsy types or syndromes. Parti-
cular attention was given to the potential of topir-
amate in establishing full seizure freedom. Both
children and adults were included.Materials and methods
Patients
Seven hundred and fourteen patients (714) were
recruited by 127 centres throughout Europe and
the Middle East. Patients were eligible if they were
at least 2 years of age, had a first diagnosis of
epilepsy within the last 5 years and presented with
any type of epileptic seizures. Epileptic seizures and
epilepsy syndromes were classified according to the
criteria of the International League Against Epilepsy
(ILAE). 15,16 Patients had to be treatment-naive or to
be a non-responder to a first course of AED mono-
therapy, and not in need of combination treatment.
Exclusion criteria were: pseudo-seizures or seizures
with a treatable cause, such as metabolic disorders,
toxic exposure, active infection or neoplasm; any
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expected to interfere with the patient completing
the trial; pregnancy or lactation, history or suspi-
cion of substance abuse, participation in an inves-
tigational drug trial in the 30 days prior to trial
entry, previous use of topiramate or of more than
one other AED, and hypersensitivity to tablet con-
stituents.
Study design
This open trial included an initial titration period of
4 weeks in adults, 6 weeks in children, followed by a
6-month lasting monotherapy period, during which
topiramate could be individually adjusted according
to the response. Optionally, patients could continue
the trial up to a maximum of 13 months or until the
obligatory end of the study (set at 7 months after
enrolment of the last patient in the study). Patients
exited the study if they withdrew informed consent,
prematurely stopped topiramate treatment, had
insufficient seizure control at the maximum allowed
dose (400 mg/day in adults, 9 mg/kg/day in chil-
dren) or when another AED needed to be added to
the treatment regimen. They also could be with-
drawn if the investigator decided so for safety
reasons.
The study was performed in accordance with
the international rules of good clinical practice
(Declaration of Helsinki). The protocol was
approved by each centre’s ethics committee or by
an independent review board. Each patient or the
patient’s parent or legal guardian gave informed
consent. The study was extensively monitored with
detailed information completed at each visit and
quality data management required for phase III
studies.
Treatment
At trial entry, adults received 25 mg/day in the
evening, followed by weekly increments of 25 mg/
day during 4 weeks until reaching the target dose of
100 mg/day, given b.i.d. as morning and evening
gifts. Thereafter, the dose of topiramate could be
adjusted in function of the patient’s response with
weekly increments or decrements of 25 mg/day,
however, not exceeding 400 mg/day. In children,
topiramate was started at 0.5 mg/kg/day in the
evening, and escalated with 0.5 mg/kg/day during
6 weeks to the target dose of 3 mg/kg/day. Subse-
quent dose adjustment could not exceed 9 mg/kg/
day. If the patient used another AED at trial entry,
this was gradually withdrawn, starting at week 2 of
topiramate treatment, and over a period of three
weeks or longer if indicated. Patients were treatedfor at least 7 months (6 months of monotherapy),
and optionally for a maximum of 13 months or until
trial end.
Evaluations
Patients were evaluated at start of the trial, at end
of the titration (month 1), at the end of months 4
and 7, and if continuing beyond month 7, also at the
end of months 10 and 13. At each visit, the inves-
tigator assessed the number and type of seizures. At
start, these data were also reviewed retrospectively
for the last month, as well as the last 6 months prior
to trial entry. The 6-month retrospective informa-
tion was used to calculate the baseline mean
monthly seizure frequency. Global assessment was
performed at start and at the 7-month and 13-month
visits: the investigators rated the clinical global
impression of the patient’s medical condition on a
5-point scale (very good, good, reasonable, moder-
ate or poor). The same 5-point scale was used to
assess patients’ and physicians’ satisfaction at the 7-
month and 13-month visits.
At each visit, physicians recorded adverse events,
with their severity, relationship to topiramate treat-
ment, and outcome. Each treatment-emergent phy-
sical and neurological abnormality was recorded as
adverse event, as was any condition worsening or
requiring initiation of medication. Weight was mon-
itored throughout the trial.
Analysis and statistics
Safety data were analysed for the entire trial period
in all subjects enrolled in the trial (any type of
seizure; n = 692), efficacy data for those who had
at least one post-baseline observation (intent-to-
treat analysis, regardless of compliance with the
protocol, unless no trial medication had been taken
at all). A 7-month and 13-month endpoint analysis
was performed. Since only a limited number of
patients (n = 237) among those that decided to
continue the study beyond 7 months (n = 554) was
able to complete the full 13-month trial period due
to intervening trial closure (51% having to stop due
to trial closure), the efficacy results at endpoint
focus on the 7-month endpoint.
Mean monthly seizure frequencies during treat-
ment were calculated based on the seizures cumu-
latively counted over the treatment period, from
trial entry till each point of assessment. Mean and
median values were calculated and the change
versus baseline was assessed, using Wilcoxon
signed-rank test, two-sided at the 5% significance
level. Response rates were defined as the proportion
of patients achieving 50, 75 and 100% reduction
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Table 1 Demography and disease characteristics.
Characteristic N = 692
Gender, male:female (%) 50.9:49.1
Mean (S.D.) age (years) 29.7 (18.7)
Range age (years) 1—88
Age distribution (%)
Children 12 years 17.5
Adolescents 13—16 years 9.5
Adults 17 73.0
Percent of patients with seizures
in month prior to trial entry
86.1in mean monthly seizure frequency from trial entry
versus the 6-month retrospective baseline.
Response and seizure frequency assessments were
performed for the total patient sample and the
subgroups of patients with focal and generalised
epilepsies or epilepsy syndromes. For the subgroup
analysis, patients were classified by epilepsy syn-
drome, as assessed by the treating neurologist,
while patients with absence seizures, situation-
related seizures or an undetermined or unknown
classification were excluded.
Change in body weight during topiramate was
assessed in adults 17 years, versus the value at
start of the study and as a function of the initial body
mass index (BMI; Wilcoxon signed rank test, two-
sided at the 5% significance level).Seizure typea
Simple partial 13.4
Complex partial 24.7
Secondarily generalized 25.7
Generalized tonic-clonic 27.2
Absences 3.5
Other 3.6
Epilepsy and epilepsy syndromes
(percent of patients)
Focal 62.9
Idiopathic 6.9
Symptomatic 21.0
Cryptogenic 32.7
Unknown 2.3
Generalized 26.6
Idiopathic 20.1
Symptomatic 5.6
Symptomatic or cryptogenic 0.9
Undetermined 1.6
Situation-related seizures 0.3
Data missing/unknown 8.7
Time elapsed since first
diagnosis (months)
Mean (S.D.) 18.8 (41.3)
Median (range) 3.0 (0—486)
Baseline monthly seizure frequencyb
Mean (S.D.) 11.2 (51.9)
Median (range) 1.1 (0—999)
Prior monotherapy with one AED
(percent of patients)
42.9
Main prior AEDs (%)
Carbamazepine 34.7
Valproate 33.3
Phenytoin 9.1
Oxcarbazepine 8.4
Lamotrigine 6.1
a More than one seizure type possible.
b Assessed 6 months retrospectively.Results
Demography and disease characteristics
In total, 714 subjects were screened of whom 690
were included in the efficacy analysis, 692 in the
safety analysis. The reasons for excluding patients
from the efficacy or safety analysis were screening
failures in 7 cases, and missing data on efficacy or on
efficacy and safety in 2 and 15 patients, respec-
tively. Baseline and disease characteristics are given
in Table 1. About half of the patients were male
(50.9%), 17.5% were children aged 12 years or less
and 9.5% were adolescents (13—16 years).
The mean time elapsed since the first diagnosis of
epilepsy was 18.8 months, but its median was 3.0
months, indicating the majority of patients had a
recent onset of epilepsy. The epilepsies or epilepsy
syndromes were classified as focal in 62.9% of
patients and generalized in 26.6%. In the month
preceding trial entry, 86.1% of patients had suffered
from seizures (for type, see Table 1). Overall, 64.6%
of patients had a history of other disease (29.0% of
the nervous system), 41.2% presented with one or
more concomitant active diseases other than epi-
lepsy, and 45.2% received various concomitant
treatments.
Prior to trial entry, 42.9% of all patients enrolled
had received monotherapy with one AED other
than topiramate (see Table 1 for AED used). The
reason for switching to topiramate was failure of
efficacy in 61.6% of these patients, failure of toler-
ability in 24.9% and both in 13.1%. Failure of
efficacy was the main reason to switch to topir-
amate for all prior AEDs, but tolerability was the
single cause in more than one fourth of patients
previously on carabamazepine or valproate, while
it was involved as a reason for failure (with orwithout efficacy) in more than 40% of the patients
on valproate, oxcarbazepine, lamotrigine and ben-
zodiazepines.
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Figure 1 Distribution of topiramate monotherapy doses
in adults at the 7-month endpoint.
Table 2 Reason for withdrawal during topiramate treatment.
Percent of patients
First 7 months (N = 692) Subsequent 6 months (N = 554)
Patients withdrawing due to
Insufficient tolerability 6.2 1.1
Insufficient efficacy 4.5 2.5
Insufficient tolerability and efficacy 2.6 0.7
Lost to follow-up 1.9 0.2
Withdrew consent 1.3 0.4
Lack of compliance 1.2 0.7
Protocol violation 0.9 0.4
Epilepsy improved 0.6 0.2
Other reasonsa 0.9 —
Total withdrawals 19.9 6.1
a Other: pregnancy (n = 1), hospitalised (n = 4) and death after stroke and myocardial infarction (n = 1) not causally linked to
topiramate.Completion/withdrawal information
The study retention during the mandatory 7-month
study period, including 4- to 6-week titration and up
to 6 months of monotherapy, was high (80%). The
reasons for dropout are listed in Table 2. The reasons
were insufficient tolerability in 6.2% of patients,
insufficient efficacy in 4.5% and both in 2.6%; 1.3%
of patients withdrew consent. Among the 554
patients continuing beyond 7 months (optional fol-
low-up period), a total of 3% dropped out because of
insufficient efficacy and/or tolerability. Two hun-
dred and thirty-seven patients completed the full
13-month treatment period (treatment was stopped
earlier in 51% due to intervening trial closure).
Topiramate dosing
In the patients taking an AED prior to trial entry, the
AEDwas tapered offwithin 25.6 (S.D. 15.6) days after
starting topiramate. Fig. 1 illustrates the distribution
of doses in adults at the 7-month endpoint. Table 3
lists the mean and median topiramate monotherapy
doses, as well as their range, as used by adults (17
years), adolescents (13—16 years), and children (12
years) at the 7-month endpoint. The median doses
were 125 mg/day, 125 mg/day and 3.3 mg/kg/day,Table 3 Mean and median dose of topiramate at the 7-mo
N
mg/day
Adults (17 years) 441
Adolescents (13-16 years) 54
mg/kg/day
Children (12 years) 114respectively: 100 mg was the most commonly used
daily dose in adults, 42.9% used 100 mg daily.
Seizure response
Mean monthly seizure frequency at baseline was
11.2 (median 1.1, including all seizures) and was
higher in focal than generalized epilepsies (Fig. 2,
excluding absences) and was significantly reduced
at all visits during topiramate treatment, both in the
total study population and the epilepsy subgroups
(p < 0.001 for change versus baseline).nth endpoint.
Dose
Mean (S.D.) Median Range
154 (78) 125 25—700
151 (77) 125 25—400
3.9 (2.0) 3.3 1.3—13.0
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Figure 2 Evolution of the mean monthly seizure fre-
quency in focal and generalized epilepsies. Patients with
absences seizures, situation-related seizures or seizures
with an undetermined or unknown classification were
excluded. [For calculation of mean monthly seizure fre-
quencies, seeMaterials andmethods; *p < 0.005—0.001 for
changes during treatment when compared to baseline.]
Figure 3 Response rates during topiramate titration
(month 1) and monotherapy (data at months 4—7, and
at the 7-month endpoint): proportion of patients with at
least 50%, 75% and 100% reduction in mean monthly
seizure frequency from trial entry vs. baseline. [Data
presented at a particular visit are based on the number
of patients still in the trial and with data on seizures for
that particular visit. The endpoint value includes the data
from all patients at their last observation up to month 7.]During the first 7 months of the study, 44.3% of
patients were seizure-free (Fig. 3). At the different
visits, 72.0—83.0% of patients achieved at least 50%
seizure reduction, and 65.0—69.7% at least 75%
reduction. Table 4 lists the response rates at the
7-month endpoint, in the complete study population
and each of the epilepsy subgroups. In the group
with focal epilepsies, 39.4% of patients were sei-
zure-free, while 73.9% achieved at least 50% seizure
control. In the group with generalized epilepsies,
61.5% remained in remission, while 83.8% achieved
at least 50% seizure reduction.
Similar response rates were obtained at the
13-month visit and at the 13-month endpoint:
35.3 and 40.8% of patients were seizure-free at
these points, respectively. A Kaplan—Mayer analysis
of the time-to-first seizure indicated that the
majority of patients who relapsed (>40% of all
the patients) did so within the first 6 weeks of the
study, corresponding to the titration period.
Tolerability
Overall, adverse events were reported in 65.3% of
patients, serious adverse events in 7.8%. Insufficient
tolerability was a reason for dropout in a total ofTable 4 Response rates to topiramate monotherapy (inten
least 50, 75 and 100% reduction in mean monthly seizure fr
Epilepsie
All (N =
Response at 7-month endpoint: percent of patients achievi
At least 50% seizure reduction 76.3
At least 75% seizure reduction 63.9
100% seizure reduction (seizure freedom) 44.38.8% of patients in the first 7 months and in 1.8% of
patients followed between 7 and 13 months
(Table 2). The most frequent adverse events are
listed in Table 5. Paraesthesia was the most common
adverse event (in 16% of patients), but rarely a
reason to stop treatment (in less than 1%). Kidney
stones were reported in two patients. This adverse
event was not rated as ‘serious’, but it led to trial
exit in one patient.
The causal relationship of adverse events was
rated ‘very likely’ in 12.0% of the reported adverse
events, ‘probable’ in 15.2% and ‘possible’ in 23.7%.
In the majority of adverse events, no action was
taken; in 7.6% of the events, the dose was adjusted
and in 9.2%, topiramate was stopped permanently.
Body weight
Prior to trial entry, 55.2% of adult patients had a BMI
below 25, while 44.8% were overweight to obese.
During topiramate, mean weight (S.D.) decreased
significantly from 73.4 kg (15.7) to 70.8 kg (15.6) at
the 7-month endpoint. The effect was the mostt-to-treat analysis): percentage of patients achieving at
equency from trial entry versus baseline.
s and epilepsy syndromes
661) Focal (N = 421) Generalized (N = 148)
ng
73.9 83.8
60.6 75.7
39.4 61.5
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Table 5 Adverse events during topiramate monother-
apy.
All subjects
(N = 692)
Total eventsa 1475
Most frequently reported adverse
events (5% of patients) (%)
Paraesthesia 15.9
Headache/cephalalgia 13.0
Loss of appetite/anorexia 8.4
Weight decrease 8.4
Nausea 7.1
Dizziness 6.5
Somnolence 5.2
Percent of patients with one
or more adverse events (any type)
65.3
One adverse event 21.8
Two adverse events 15.3
Three adverse events 7.8
At least four adverse events 20.4
Percent of patients with one or
more serious adverse events
7.8
a Any physical abnormality or condition worsening or requir-
ing medication during the trial had to be reported as adverse
event.pronounced during the first 4 months of topiramate
treatment, after which it was maintained through-
out the trial (p < 0.001 for change versus baseline
at all visits). Weight loss was more pronounced in
overweight patients: at the 7-month endpoint, the
mean weight change was 1.9 kg in patients with a
BMI lower than 25 kg/m2,2.6 kg in those with a BMI
between 25 and 30 kg/m2, and 4.7 kg in patients
with a BMI of at least 30 kg/m2 (p < 0.001 versus
baseline in all BMI classes).
Clinical global impression and satisfaction
At the 7-month endpoint, the clinical global impres-
sion was rated by the investigators as ‘very good’ in
40.6% of patients, ‘good’ in 37.1% and ‘reasonable’
in 13.9%. The result was ‘poor’ in 3.8% of patients,
and ‘moderate’ in 4.7%. Patient satisfaction with
treatment was rated as ‘very good’ in 41.3% of the
patients and ‘good’ in 30.8%. Similar rates of satis-
faction were obtained by physician rating (40.7 and
30.3%, respectively).Discussion
This study was performed in a mixed group of
patients with a broad spectrum of epilepsies, either
being treatment-naive or having failed one priorAED. Although such approach enrolling a broad
spectrum of patients has restrictions, because epi-
lepsies with different prognoses are pooled, it
reflects clinical practice. Often, the exact diagnosis
is not yet known when the patient presents first, and
by the time AED treatment is started. Even in
specialized centres, an epilepsy syndrome diagnosis
or epilepsy classification is often difficult after the
initial seizures. Diagnosis evolves with more cer-
tainty over time. Thus, in such circumstances, the
use of a broad-spectrum AED is desirable, when
treatment is needed.
This study shows that, in a setting closely follow-
ing routine practice, a high-study retention can be
obtained during flexibly dosed topiramate mono-
therapy (80%). Although the study is limited by its
open design, the results suggest good tolerability
and high adherence to treatment during topiramate
monotherapy. Moreover, seizure control was
achieved at topiramate dosages lower than those
used in previous randomised controlled trials (med-
ian topiramate dose: 125 mg/day in adults and ado-
lescents and 3.3 mg/kg/day in children below the
age of 12). Over the total study period (titration
inclusive), seizure freedom was observed in over
40% of patients. There were no major unexpected
differences in efficacy between types of epilepsy.
Fairly sustained response rates were observed
during 7—13 months in over 200 patients who were
followed up for 1-year on monotherapy; the major-
ity of relapses and dropouts had already occurred
during the titration period. Long-term remission was
thus obtained with topiramate in a majority of
patients who completed the titration phase without
seizures.
Comparison with other monotherapy studies of
topiramate or other AEDs is hampered by differ-
ences in patient selection, trial design and, in par-
ticular, by the broad spectrum of epilepsies studied
in this trial. Nevertheless, some aspects deserve
discussion. The patient retention in this study was
very high: only 20% of patients withdrew during the
first 7 months. This observation is even more rele-
vant when considering that 42.9% of patients
enrolled in this study failed to respond to a prior
AED for reasons of insufficient efficacy or tolerabil-
ity. The dropout rate was similar to those reported
for low-dosed topiramate in two controlled studies
allowing dose adjustment (19—21%).12,14 The 80%
retention rate observed after 7 months in our study
was higher than reported after 6—7 months mono-
therapy with other AEDs: below 68% with lamotri-
gine,17—19 43—56% with two different dosages of
gabapentin,20 56% with phenytoin,18 56—65% with
carbamazepine,17,20 and 57% with conventional
AEDs, including carbamazepine, phenytoin and
378 R. Guerrini et al.valproate.19 However, one study in newly diagnosed
epilepsy patients found comparable retention rates
with topiramate 100 mg/day and carbamazepine
600 mg/day (fixed target doses), albeit lower than
for valproate (1250 mg/day),13 while another study
comparing lamotrigine and carbamazepine (in
adjustable doses) reported similar 6-month with-
drawal rates as in our study.21 The findings suggest
that the ‘‘flexible’’ dose adjustment may be a factor
contributing to longer retention of patients on
treatment with AEDs. The high rate of patient
retention we observed is also in line with the ratings
of satisfaction with treatment, being ‘good’ to ‘very
good’ in more than 70% of patients, both when rated
by patients and physicians.
A second relevant observation is the high rate of
seizure freedom, obtained in this study with low-
dosed topiramate when used as first or second AED
monotherapy for a broad spectrum of seizures. In an
observational study of 525 patients, Kwan and Bro-
die reported seizure freedom in 69% of patients on
follow-up, but only 47% had responded to the first
AED, 13% to the second AED.22 Many studies report
rates of seizure freedom during 4—6 months of
monotherapy with various AEDs, mostly varying
between 32 and 60%.17—19,20,23 Yet, comparison
with these studies is difficult, not only because
the patient populations may differ in types and
severity of epilepsy, but also because the seizures,
or the patients developing seizures, during the
titration period were usually censored for calcula-
tion of the response during monotherapy: for
instance, these accounted for 40—56% of patients
on various doses of lamotrigine and carbamazepine
in one study.17 In our study, about 40% of patients
had recurrences during the titration period, yet
more than half of these patients continued in the
trial. Despite the inclusion of the seizures during
the titration period for calculation of the response
rates, still more than 40% patients were seizure-
free after 7—13 months of study. Overall, the
response rates with topiramate in our study seem
to compare well with those reported for other AEDs
that currently are recommended for first-line use as
monotherapy. In particular, our data suggest that
topiramate may be effective at low monotherapy
doses.
On the other hand, seizure freedom in our study
was not as favourable as the rates that were
reported after 6 months of topiramate monotherapy
in newly diagnosed treatment-naive or prior treat-
ment-responding patients (71% seizure-free with
50 mg/day, and 83% with 400 mg/day),14 and in a
small series of newly diagnosed adults (92% seizure-
free with 200 mg/day).24 In another study in
patients with focal epilepsy,12 the degree of seizurefreedom observed at 4 months with 25—50 mg/day
of topiramate was similar to the rate obtained in our
study after 7 months (39%), while it was 54% with
200—500 mg/day of topiramate. However, the
higher dose was associated with more adverse
events.12 Taken together, these observations indi-
cate that patients with refractory focal epilepsy
may benefit from further up-titration of topiramate
until the optimal balance between seizure control
and tolerability is reached. The rate of seizure
freedom in the present study may also be not as
high as expected from other studies, in part due to
the rather heterogeneous patient sample. As can be
noted from the mean baseline monthly seizure
rates, a subset of our patients had fairly high seizure
rate at start of treatment for newly diagnosed or
new-onset epilepsies.
Overall, topiramate was well tolerated. Only
8.8% of patients withdrew in the first seven months
because of lack of tolerability. Paraesthesia, the
most common adverse event, was rarely a reason
for withdrawal. Nephrolithiasis was observed in two
(0.2%) patients, which compares to the incidence in
the normal population.25 Several ocular adverse
events indicative of infection or aspecific ocular
symptoms were reported, but there was no report
of acute glaucoma. The effect of topiramate on
weight was most pronounced in obese patients
(BMI30). This finding confirms earlier observations
that topiramate may be advantageous in patients
needing weight loss.26,27
In conclusion, in open naturalistic setting low,
flexibly dosed topiramate appeared suitable for
initiation, both as first and second-line monother-
apy. In line with the controlled studies in specific
epilepsy subtypes, it was found to result in good
response rates, high patient retention and good
tolerability, when used for a broad range of epilep-
sies.Acknowledgements
We gratefully acknowledge all participants of the
topiramate TOP-INT-51 investigators’ group: Bel-
gium: Dr. L. Lagae, Leuven; Dr. B. Sadzot, Lie`ge;
Dr. P. Van Bogaert, Brussels; Dr. K. van Rijckevorsel,
Ottignies; Dr. C. Willems, Hasselt; Bulgaria: Dr. A.
Alexiev, Sofia; Dr. S. Bojinov, Pleven; Dr. D. Chav-
darov, Sofia; Dr. G. Ganeva, Sofia; Dr. D. Minchev,
Varna; Croatia: Dr. S. Hajnsek-Propadalo, Zagreb;
Dr. I. Lusic, Split; Dr. B. Marusic-Della Marina,
Zagreb; Dr. E. Paucic-Kirincic, Rijeka; Dr. Z. Polja-
kovic, Zagreb; Dr. D. Skarpa, Zagreb; Dr. I. Valic,
Split; Denmark: Dr. A. Andersen, Glostrup; Dr. B.
Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting 379Anthonisen, Hvidovre; Dr. M. Grønbech-Jensen,
København; Dr. G. Gulliksen, Viborg; Dr. J. Jansen,
Næstved; Dr. K. Luhdorf, Roskilde; Dr. J. Mai,
Horsens; Dr. S. Østergaard, Vejle; Dr. T. Sørensen,
Hillerød; Dr. P. Thorvaldsen, Gentofte; Dr. M. Worm,
Sønderborg; Estonia: Dr. I. Talvik, Tartu.; France: Dr.
M. Barthez, Tours; Dr. B. De Toffol, Tours; Dr. P.
Derambure, Lille; Dr. E. Hirsch, Strasbourg; Dr. E.
Josien, Bethune; Dr. J. Pedespan, Bordeaux; Dr. C.
Rouselle, Pierre-Benite; Great-Britain: Dr. P. McKee,
Middlesbrough; Dr. P. Smith, Cardiff; Greece: Dr. S.
Balogiannis, Thessaloniki; Dr. N. Diamantopoulos,
Patras; Dr. K. Karageorgioy, Athens; Dr. A. Kyritsis,
Ioannina; Dr. I. Mylonas, Thessaloniki; Dr. A. Papa-
vasiliou, Athens; Dr. H. Piperidoy, Alexandroupoulis;
Dr. D. Vassilopoulos, Athens; Israel: Dr. M. Neufeld,
Tel Aviv; Dr. M. Rabey, Zrifin; Italy: Dr. U. Aguglia,
Reggio Calabria; Dr. P. Balestri, Siena; Dr. G. Capo-
villa, Mantova; Dr. G. Cristofori, Pordenone; Dr. R. Di
Perri, Messina; Dr. A. Ganga, Sassari; Dr. P.G. Gar-
ofalo, Vicenza; Dr. G.L. Gigli, Udine; Dr. G. Gobbi,
Bologna; Dr. M. Manfredi, Roma; Dr. M.G. Marciani,
Roma; Dr. A. Martinuzzi, Treviso; Dr. R. Michelucci;
Bologna; Dr. F. Minicucci, Milano; Dr. A. Romeo,
Milano; Dr. F. Sasanelli, Milano; Dr. P. Veggiotti,
Pavia; Dr. C. Zucca, Lecco; Saudi Arabia: Dr. S. Al-
Yamani, Riyadh; Dr. M. Jan, Jeddah; Dr. B. Yaqub,
Riyadh; Kuwait: Dr. A. Al Shubaili; Safat; Latvia: Dr.
E. Vtols, Riga; Lebanon: Dr. M. Mikati, Beirut; Dr. P.
Bejjani, Byblos; Dr. N. Riachi, Beirut; The Nether-
lands: Dr. G.W.A. Den Hartog, Bergen op Zoom; Dr.
J.J.M. Hagemans, Helmond; Dr. J.P.M. Hillegers,
Amsterdam; Dr. D.J. Kamphuis, Delft; Dr. R.W.M.
Keunen, Den Haag; Dr. P.J.J. Koehler, Heerlen; Dr.
Q.A.H. Leyten, Arnhem; Dr. P.H.M. Pop, Venray; Dr.
M.G. Smits, Ede; Dr. H.J.M. Van Der Leeuw, Tilburg;
Dr. C.A. Van Donselaar, Rotterdam; Dr. M.M. Veering,
Alkmaar; Norway: Dr. C. Albretsen, Tromso¨; Dr. T.
Hagen, Drammen; Dr. B. Ka˚ss, Kristiansand; Dr. E.
Kinge, Sandvika; Dr. A. Lillebo¨, Bergen; Dr. T. Svend-
sen, Lillehammer; Dr. E. Taubo¨ll, Oslo. Oman: Dr. D.
Deleu, Al Khod; Dr. R. Koul, Al Khod; Pakistan: Dr. S.
Alam, Peshawar; Dr. S.M. Baig, Karachi; Dr. H.R.
Chaudry, Lahore; Dr. K. Iqbal, Multan; Poland: Dr.
J. Majkowski, Warszawa; Dr. L. Michalak, Gdansk;
Portugal: Dr. L.B. Almeida, Almada; Dr. L. Cunha,
Doimbra; Dr. J.M.L. Lima, Porto; Dr. I. Luzeiro,
Coimbra; Dr. F. Pinto, Lisboa; Dr. J.P. Viana, Lisboa;
Qatar: Dr. M. Bessisso, Doha; Russia: Dr. A. Fedin,
Moscow; Dr. M. Nikanorova, Moscow; Slovenia: Dr. D.
Butinar, Ljubljana; Dr. A. Gacnik, Maribor; Dr. P.
Gradisnik, Maribor; Dr. I. Ravnik, Ljubljana; Slova-
kia: Dr. D. Buranova, Bratislava; Dr. V. Donath,
Banska Bystrica; Dr. M. Kuchar, Bratislava; Dr. L.
Lipovsky, Bratislava; Dr. M. Paucova, Kosice; Dr. B.
Pithova, Martin; Sweden: Dr. B. Borre, Helsingborg;Dr. L. Brattstro¨m, Kalmar; Dr. A. Landtblom, Motala;
Dr. B. So¨derfeldt, Linkoping; United Arab Emirates:
Dr. R. McLachlan, Abu Dhabi.
We further thank Suzy Huijghebaert, La Hulpe,
Belgium for her assistance in preparing this manu-
script, Sandra Opfergelt, from Janssen-Cilag, The
Netherlands for data management and the local
trial coordinators: Belgium: E. De Schrijver; Bul-
garia: H. Ivanova; Croatia: Z. Predic; Denmark: J.
Nilsson; Estonia: T. Parik; France: C. Tetelin; Great-
Britain: L. Hannis, S. Needham; Greece: A. Bene-
kou; Gulf: A. James; Israel: O. Shai; Italy: M. Adami;
Saudi Arabia: A. Khedr; Latvia: S. Markote; Leba-
non: H. Bibi; The Netherlands: E. Gorter; Norway:
B. Varaas; Pakistan: S.H. Lodi; Poland: P. Go´rski;
Portugal: J. Medonc¸a; Russia: A. Kutermin; Slove-
nia: S. Bizilj; Slovakia: L. Durechova; Sweden: H.
Kernell.References
1. King MA, Newton MR, Jackson GD, Fitt GJ, Mitchell LA,
Silvapulle MJ, et al. Epileptology of the first-seizure presen-
tation: a clinical, electroencephalographic, and magnetic
resonance imaging study of 300 consecutive patients. Lancet
1998;352:1007—11.
2. Gil-Nagel A. Review of new antiepileptic drugs as initial
therapy. Epilepsia 2003;44(Suppl. 4):3—10.
3. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T,
Harden CL, et al. Efficacy and tolerability of the new anti-
epileptic drugs I: treatment of new onset epilepsy. Report of
the Therapeutics and Technology Assessment Subcommittee
and Quality Standards Subcommittee of the American Acad-
emy of Neurology and the American Epilepsy Society. Neu-
rology 2004;62:1252—60.
4. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T,
Harden CL, et al. Efficacy and tolerability of the new anti-
epileptic drugs II: treatment of refractory epilepsy. Report of
the Therapeutics and Technology Assessment Subcommittee
and Quality Standards Subcommittee of the American Acad-
emy of Neurology and the American Epilepsy Society. Neu-
rology 2004;62:1261—73.
5. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of
topiramate on sustained repetitive firing and spontaneous
bursting in cultured hippocampal neurons. Epilepsia
1993;34(Suppl. 2):123.
6. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The
novel anticonvulsant topiramate enhances GABA-mediated
chloride flux. Epilepsia 1993;34(Suppl. 2):122—3.
7. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH.
Topiramate enhances GABA-mediated chloride flux and
GABA-evoked chloride currents in murine brain neurons
and increases seizure threshold. Epilepsy Res
1997;28:167—79.
8. Shank RP, Gardocki JF, Vaugth JL, Davis CB, Schupsky JJ, Raffa
RB, et al. Topiramate: preclinical evaluation of a structurally
novel anticonvulsant. Epilepsia 1994;35:450—60.
9. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation
of high-voltage-activated calcium channels in dentate
granule cells by topiramate. Epilepsia 2000;41(Suppl. 1):
52—60.
380 R. Guerrini et al.10. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP.
Anticonvulsant O-alkyl sufamates. 2,3:4,5-bis-O-(1-methyl-
ethylidene)-b-D-fructopyranose sulfamate and related com-
pounds. J Med Chem 1987;30:880—7.
11. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate mono-
therapy for partial onset seizures. Epilepsia 1997;38:294—
300.
12. Gilliam FG, et al. A dose-comparison trial of topiramate as
monotherapy in recently diagnosed partial epilepsy. Neurol-
ogy 2003;60:196—202.
13. EPMN 105 Study Group. Topiramate, carbamazepine and
valproate monotherapy: double-blind comparison in newly
diagnosed epilepsy. Acta Neurol Scand 2003;107:165—75.
14. Arroyo S, Squires L, Wang S, Twyman R. Topiramate: effective
as monotherapy in dose-response study in newly diagnosed
epilepsy. Epilepsia 2002;43(Suppl. 7):241.
15. Commission of Classification and Terminology of the Interna-
tional League Against Epilepsy. Proposal for revised clinical
and electroencephalographic classification of epileptic sei-
zures. Epilepsia 1981;22:489—501.
16. Commission on Classification and Terminology of the Inter-
national League Against Epilepsy. Proposal for classification
of epilepsies and epileptic syndromes. Epilepsia 1989;
30:389—99.
17. Reunanen M, Dam M, Yuen AWC. A randomised open multi-
centre comparative trial of lamotrigine and carbamazepine
as monotherapy in patients with newly diagnosed or recur-
rent epilepsy. Epilepsy Res 1996;23:149—55.
18. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB,
Perkin GD, et al. Lamotrigine monotherapy in newly diag-nosed epilepsy. A double-blind comparison with phenytoin.
Epilepsia 1999;40:601—7.
19. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamo-
trigine monotherapy compared with carbamazepine, pheny-
toin, or valproate monotherapy in patients with epilepsy.
Epilepsy Behav 2003;4:659—66.
20. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH,
Garofalo EA, et al. A double-blind trial of gabapentin mono-
therapy for newly diagnosed partial seizures. International
Gabapentin Monotherapy Study Group 945-77. Neurology
2001;51:1282—8.
21. Lamictal vs. Carbamazepine Group. Epilepsy Res 2001;46:
145—55.
22. Kwan P, Brodie MJ. Early identification of refractory epilepsy.
N Engl J Med 2000;342:314—9.
23. Gabapentin Study Group. Gabapentin versus lamotrigine
monotherapy: a double-blind comparison in newly diagnosed
epilepsy. Epilepsia 2002;43:993—1000.
24. Salinas-Estabane R. Topiramate monotherapy in adults with
newly diagnosed epilepsy. Adv Ther 2002;19:126—8.
25. Wasserstein AG, Rak I, Reife RA. Investigation of the mechan-
istic basis for topiramate-associated nephrolithiasis, exam-
ination of urinary and serum constituents. Epilepsia 1995;
36(Suppl. 3):153.
26. US Topiramate Study Group. A 6-month randomised, placebo-
controlled, dose-ranging trial of topiramate for weight loss in
obesity. Obes Res 2003;11:722—33.
27. Ben-Menachem E, Axelsen M, Johanson EH, Stage A, Smith U.
Predictors of weight loss in adults with topiramate-treated
epilepsy. Obes Res 2003;11:556—62.
